3SBio Inc (1530):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:3SBio Inc (1530) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10004
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
3SBio Inc (3SBio) is a biotechnology companies that carries out the research, development, manufacturing and marketing of biopharmaceutical products. It develops recombinant, or genetically engineered, protein-based products and other pharmaceutical product candidates to address large markets with significant unmet medical needs in the areas of cancer and its supportive care, nephrology, dermatology and other therapeutic areas. the company’s products are distributed to hospitals, clinics and dialysis centers across China. The company’s products are approved for sale in Colombia, Brazil, Costa Rica, Egypt, Dominican Republic, Guatemala, El Salvador, Mongolia, Laos, Pakistan, Sri Lanka, Myanmar, Philippines, Paraguay, Thailand and Trinidad and Tobago. 3SBio is headquartered in Shenyang, China.

3SBio Inc (1530) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
3SBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
3SBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
3SBio Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
3SBio Acquires Anti-TNF Monoclonal Antibody Technology from Apexigen 11
3SBio Acquires Patents For DJ5, Potential Renal Failure Therapy, From SIMM 12
Venture Financing 13
Refuge Biotech Raises USD25 Million in Series B Financing 13
Private Equity 15
3SBio CEO And Citic Private Equity Funds Complete Acquisition Of 3SBio 15
Partnerships 17
Refuge Biotechnologies Enters into Agreement with 3SBio 17
3SBio and CPE Funds to Form Joint Venture 18
3SBio Enters into Distribution Agreement with Eli Lilly 19
TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 20
3SBio Enters Into Strategic Alliance with Ascentage Pharma 21
3SBio Enters Into Joint Venture Agreement With DaVita For Dialysis Treatment 22
Licensing Agreements 23
3SBio Enters into Licensing Agreement with Alteogen 23
3SBio Enters into Licensing Agreement with PharmAbcine for DIG-KT 24
3SBio Enters into Licensing Agreement with PharmAbcine for Tanibirumab 25
3SBio Enters into Licensing Agreement with JenKem for PEG-Irinotecan 26
3SBio Enters into Licensing Agreement with DiNonA for Leukotuximab 27
Selecta Biosciences Enters into Licensing Agreement with 3SBio for Pegsiticase 28
Equity Offering 29
3SBio Completes Private Placement 29
3SBio Raises USD569 Million in IPO 30
Acquisition 31
3SBio Acquires 47% Stake in Shanghai CP Guojian Pharma for USD214 Million 31
3SBio Acquires Zhejiang Wansheng Pharma for USD86 Million 32
3SBio Acquires Sciprogen 33
3SBio Acquires Sirton Pharma 34
3SBio Inc – Key Competitors 35
3SBio Inc – Key Employees 36
3SBio Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 39
Corporate Communications 39
Jan 09, 2017: 3SBio Appoints Dr. Zhenping Zhu as President of Research & Development and Chief Scientific Officer 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
3SBio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
3SBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
3SBio Inc, Deals By Therapy Area, 2012 to YTD 2018 8
3SBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
3SBio Acquires Anti-TNF Monoclonal Antibody Technology from Apexigen 11
3SBio Acquires Patents For DJ5, Potential Renal Failure Therapy, From SIMM 12
Refuge Biotech Raises USD25 Million in Series B Financing 13
3SBio CEO And Citic Private Equity Funds Complete Acquisition Of 3SBio 15
Refuge Biotechnologies Enters into Agreement with 3SBio 17
3SBio and CPE Funds to Form Joint Venture 18
3SBio Enters into Distribution Agreement with Eli Lilly 19
TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 20
3SBio Enters Into Strategic Alliance with Ascentage Pharma 21
3SBio Enters Into Joint Venture Agreement With DaVita For Dialysis Treatment 22
3SBio Enters into Licensing Agreement with Alteogen 23
3SBio Enters into Licensing Agreement with PharmAbcine for DIG-KT 24
3SBio Enters into Licensing Agreement with PharmAbcine for Tanibirumab 25
3SBio Enters into Licensing Agreement with JenKem for PEG-Irinotecan 26
3SBio Enters into Licensing Agreement with DiNonA for Leukotuximab 27
Selecta Biosciences Enters into Licensing Agreement with 3SBio for Pegsiticase 28
3SBio Completes Private Placement 29
3SBio Raises USD569 Million in IPO 30
3SBio Acquires 47% Stake in Shanghai CP Guojian Pharma for USD214 Million 31
3SBio Acquires Zhejiang Wansheng Pharma for USD86 Million 32
3SBio Acquires Sciprogen 33
3SBio Acquires Sirton Pharma 34
3SBio Inc, Key Competitors 35
3SBio Inc, Key Employees 36
3SBio Inc, Other Locations 37
3SBio Inc, Subsidiaries 37

List of Figures
3SBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
3SBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[3SBio Inc (1530):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Alchemia Ltd (ACL):企業の財務・戦略的SWOT分析
    Alchemia Ltd (ACL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Freehold Royalties Ltd (FRU):企業の財務・戦略的SWOT分析
    Summary Freehold Royalties Ltd (Freehold Royalties), formerly Freehold Royalty Trust is an oil and gas company that offers oil and gas operation and financial performance. Its oil and gas assets generate income from natural gas, crude oil, natural gas liquids and potash deposits. It provides horizon …
  • Exiqon AS-医療機器分野:企業M&A・提携分析
    Summary Exiqon A/S (Exiqon), a subsidiary of Qiagen NV is a medical device company that develops, manufactures and markets molecular diagnostic test products. The company’s product categories include microRNA research, incRNA research, mRNA research, DNA research, custom oligos and other reagent pro …
  • B&G Foods, Inc.:企業のM&A・事業提携・投資動向
    B&G Foods, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's B&G Foods, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Shin-Etsu Chemical Co Ltd (4063):企業の財務・戦略的SWOT分析
    Shin-Etsu Chemical Co Ltd (4063) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • FalconStor Software Inc (FALC):企業の財務・戦略的SWOT分析
    Summary FalconStor Software Inc (FalconStor) is a technology company that offers data protection and storage virtualization solutions. The company offers freestor, continuous data protector, and network storage server. It offers freestor, which supports to manage data to deliver real-time informatio …
  • Xhale Inc:製品パイプライン分析
    Summary Xhale Inc (Xhale) is a medical technology company that develops and commercializes patient-centric monitoring solutions for the healthcare industry. The company offers platforms such as SMART and assurance platforms. Its products include therapeutic drug monitoring, metabolic pathway assessm …
  • Emera Inc (EMA):企業の財務・戦略的SWOT分析
    Emera Inc (EMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Australian Pharmaceutical Industries Ltd (API):企業の財務・戦略的SWOT分析
    Australian Pharmaceutical Industries Ltd (API) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Hexion Inc:企業の戦略的SWOT分析
    Hexion Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Michigan Public Power Agency:企業の戦略的SWOT分析
    Michigan Public Power Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • The Sage Group plc (SGE):企業の財務・戦略的SWOT分析
    The Sage Group plc (SGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • MeiraGTx Holdings Plc (MGTX):製薬・医療:M&Aディール及び事業提携情報
    Summary MeiraGTx Holdings Plc (MeiraGTx) is an independent clinical-stage gene therapy company that focuses on the development of therapeutics for the treatment of eye, salivary gland and neurodegenerative diseases. The company’s pipeline of preclinical and research programs include AAV-CNGB3, for a …
  • Groupe Bruxelles Lambert SA (GBLB):企業の財務・戦略的SWOT分析
    Groupe Bruxelles Lambert SA (GBLB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Genetic Analysis AS:医療機器:M&Aディール及び事業提携情報
    Summary Genetic Analysis AS (Genetic Analysis) is a molecular diagnostic company that mapping of microbiota by utilizing the GA-map technology to develop IVD tests in various diseases. The company develops gene-based routine tests for the mapping and diagnosis of diseases related to dysbiosis and ba …
  • Ipsen S.A.:企業の戦略・SWOT・財務分析
    Ipsen S.A. - Strategy, SWOT and Corporate Finance Report Summary Ipsen S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Pacific Edge Ltd (PEB):企業の財務・戦略的SWOT分析
    Summary Pacific Edge Ltd (PEB) is a diagnostics company that develops, discovers, and commercializes diagnostic tests for the early detection and monitoring of cancer. The company provides lead product such as Cxbladder, a non-invasive laboratory test for the detection of bladder cancer. It also dev …
  • GCL-Poly Energy Holdings Ltd:企業の発電所・SWOT分析2018
    GCL-Poly Energy Holdings Ltd - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • FitLife Brands Inc:企業の戦略・SWOT・財務情報
    FitLife Brands Inc - Strategy, SWOT and Corporate Finance Report Summary FitLife Brands Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Fremont Petroleum Corp Ltd (FPL):企業の財務・戦略的SWOT分析
    Fremont Petroleum Corp Ltd (FPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆